StockData
Inmune Bio, Inc. logo

Inmune Bio, Inc. (INMB) stock

INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$1.03+0.07 (+7.29%)

Close on Nov 18, 2026Market cap $28.59MP/E –Yield –

Inmune Bio operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Inmune Bio's operating income for the twelve months ending Jun 30, 2026 was -$20.20M. For fiscal 2025 it was -$47.38M. The highest annual figure on record is -$981.48K in fiscal 2017.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$47.38M–
FY2024Dec 31, 2024-$42.64M–
FY2023Dec 31, 2023-$29.74M–
FY2022Dec 31, 2022-$25.95M–
FY2021Dec 31, 2021-$29.15M–
FY2020Dec 31, 2020-$12.23M–
FY2019Dec 31, 2019-$7.76M–
FY2018Dec 31, 2018-$12.44M–
FY2017Dec 31, 2017-$981.48K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$1.48M–
Q1 FY2026Mar 31, 2026-$5.81M–
Q4 FY2025Dec 31, 2025-$5.47M–
Q3 FY2025Sep 30, 2025-$7.43M–
Q2 FY2025Jun 30, 2025-$24.57M–
Q1 FY2025Mar 31, 2025-$9.91M–
Q4 FY2024Dec 31, 2024-$9.47M–
Q3 FY2024Sep 30, 2024-$12.29M–
Q2 FY2024Jun 30, 2024-$9.87M–
Q1 FY2024Mar 31, 2024-$11.02M–
Q4 FY2023Dec 31, 2023-$8.38M–
Q3 FY2023Sep 30, 2023-$8.53M–
Q2 FY2023Jun 30, 2023-$6.41M–
Q1 FY2023Mar 31, 2023-$6.42M–
Q4 FY2022Dec 31, 2022-$5.64M–
Q3 FY2022Sep 30, 2022-$7.44M–
Q2 FY2022Jun 30, 2022-$6.39M–
Q1 FY2022Mar 31, 2022-$6.48M–
Q4 FY2021Dec 31, 2021-$9.03M–
Q3 FY2021Sep 30, 2021-$9.02M–
Q2 FY2021Jun 30, 2021-$6.55M–
Q1 FY2021Mar 31, 2021-$4.55M–
Q4 FY2020Dec 31, 2020-$3.21M–
Q3 FY2020Sep 30, 2020-$4.82M–
Q2 FY2020Jun 30, 2020-$2.11M–
Q1 FY2020Mar 31, 2020-$2.09M–
Q4 FY2019Dec 31, 2019-$2.33M–
Q3 FY2019Sep 30, 2019-$3.08M–
Q2 FY2019Jun 30, 2019-$428.42K–
Q1 FY2019Mar 31, 2019-$1.91M–
Q4 FY2018Dec 31, 2018-$1.88M–
Q3 FY2018Sep 30, 2018-$1.54M–
Q2 FY2018Jun 30, 2018-$6.17M–
Q1 FY2018Mar 31, 2018-$2.85M–

More Inmune Bio figures

See a number that looks wrong?